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We investigated the eﬀects of orange juice (OJ) or hesperidin, a component of OJ, on the pharmacokinetics of pravastatin (PRV)
and the expression of both protein and mRNA of multidrug resistance-associated protein 2 (Mrp2) in the rat small intestine and
liver. Eight-week-old male Sprague-Dawley rats were used in this study. OJ or a 0.079% hesperidin suspension was administered
orally for 2 days. Tap water was given as a control. A single dose of PRV at 100mg/kg p.o. was administered after 2 days of OJ,
hesperidin, or tap water ingestion. The AUC, Cmax,a n dt1/2 values of PRV were signiﬁcantly increased in OJ group. Mrp2 protein
and mRNA levels in the small intestine and liver, respectively, were signiﬁcantly decreased after the ingestion of OJ. The same
results were obtained with hesperidin. These results suggest that thechanges in PRV pharmacokinetic parameters andthe decrease
in Mrp2 expression caused by OJ are due to hesperidin in the juice.
1.Introduction
Many reports have conﬁrmed that grapefruit juice (GFJ)
alters the bioavailability of lipophilic drugs due to its
inhibitory eﬀect on CYP3A4 or on the eﬄux transporter P-
glycoprotein [1, 2]. However, there are few reports on the
eﬀects of other types of juice on the pharmacokinetics of
hydrophilic drugs.
Pravastatin (PRV) is an HMG-CoA reductase inhibitor
administered as a sodium salt of the active hydroxy acid
form. The bioavailability of PRV with oral administration
is about 20% of the total dose [3]. Dresser and Bailey
reported that orange juice (OJ) aﬀects the pharmacokinetics
of fexofenadine [2]. However, the role of OJ in the pharma-
cokinetics of hydrophilic drugs was unclear. Therefore, we
investigated the eﬀects of OJ (short-term ingestion) on PRV
pharmacokinetics and found that ingesting OJ increased the
area undertheplasma drugconcentration-time curve(AUC)
and peak plasma concentration (Cmax)o fP R Vi nr a t s[ 4].
On the other hand, it is known that multidrug resistance-
associated protein 2 (MRP2) is involved in the transport of
PRV [5, 6] .T h u s ,w ea l s oi n v e s t i g a t e dt h ee ﬀects of short-
term OJingestion on thelevelofMrp2 proteinand mRNAin
the small intestine and liver. However, there was no change2 Journal of Biomedicine and Biotechnology
in Mrp2 levels after short-term OJ ingestion. Lilja et al. [7]
reported a study in which volunteers drank 200mL double-
strength juice three times daily for 2 days. Dresser and Bailey
[2] conducted a study in which the volume and schedule of
OJ administration were 300mL with 2 drug tablets, followed
by 150mL every 0.5 to 3.0h (total volume, 1.2L). Based
on those reports, we selected the dose and dosage schedule
of OJ in the current study (2-days OJ ingestion). Since a
decrease in Mrp2 expression after 2-day OJ ingestion was
observed, we reexamined the eﬀects of 2 day of OJ on PRV
pharmacokinetics.
The predominant ﬂavanone in the serum after OJ
ingestion is hesperetin [8, 9]. This ﬂavanone is common in
plants, where they are conjugated to glycosides. Hesperetin
is present in oranges as hesperetin-7-O-rutinoside (hes-
peridin).Hesperidinismetabolizedtohesperetininthesmall
intestineandassumesitsactiveform.Wealsoinvestigatedthe
inﬂuence of hesperidin on the pharmacokinetics of PRV and
the expression of Mrp2 in the rat small intestine and liver.
2.Materialsand Methods
2.1. OJ Study I. Eight-week-old male Sprague-Dawley rats
were used in this study. OJ was administered orally every
hour for a total of 8 times on the 1st day and 5 times on the
2nd day. The initial dose was 5mL/kg, and each consecutive
dose was 2.5mL/kg. Tap water was given to the control
group. A single dose of PRV at 100mg/kg p.o. was admin-
istered 1h after the last ingestion of OJ or tap water. Serial
blood samples were collected intravenously from the tail
vein. Venous blood samples were placed in tubes containing
5μL of0.2M ethylenediaminetetraacetic acid(EDTA)15,30,
45, 60, 75, 90, 120, 150, and 180min after the administration
of PRV to measure plasma PRV concentrations. Blood
sampleswere immediately centrifugedat2000gfor10minat
4◦C for plasma collection and stored at −20◦C until analysis.
PRV levels were measured according to the methods
of Otter and Mignat [10] and Lacona et al. [11]. The
internal standard solution was prepared by dissolving triam-
cinolone acetonide (Sigma Chemical, St. Louis, MO, USA)
in methanol and a 300μL aliquot containing 1μg/mL of this
internal standard solution was added to 100μLo fp l a s m a .
Then, 900μL of water was added and mixed. The samples
were loaded on a C18 preparatory solid-phase extraction
column (Sep-Pak cartridge, Waters Co., Milford, MA, USA)
conditioned with 2mL of methanol and 3mL of water. The
cartridges were then washed with 2mL of 80% methanol
and allowed to dry for 60 min under air. After evaporation,
the residue was dissolved in 500μL of methanol and allowed
to dry for an additional 15min. Finally, the samples were
eluted with 300μL of methanol and 100μLw a si n j e c t e do n
the HPLC column. The chromatographic system consisted
of a DP-8020 pump, an AS-8020 autosampler, and a UV
detector(UV-8020,TosohCo.,Tokyo,Japan).Separationwas
achieved on a Cosmosil 5C18-AR column (5μm particlesize,
4.6 × 150nm ID, Nakalai Tesque, Kyoto, Japan). The
chromatographic data were collected and processed with
an LC-8020 multistation system (Tosoh Co.). The mobile
phase was 74% ammonium phosphate (0.05M, pH 3.5) and
26% acetonitrile. The ﬂow rate was 1.0mL/min with column
temperaturesmaintained at37◦C.TheUVdetectorwassetat
239nm. Underthese conditions, the retention times for PRV
and the internal standard were 13 and 23min, respectively.
The standard curve of PRV was linear over the range tested
(10pg/mL–500ng/mL; slope 4.156, intercept −1.117, R2 =
0.999 [HPLC peak area versus PRV content]). The interassay
and intra-assay coeﬃcients of variation were within 5.12%
and 1.42%, respectively.
Pharmacokinetic parameters for PRV were obtained
from plasma concentration-time proﬁles. AUC(0–3.0h) was
determinedusingthetrapezoidalrule.Thet1/2 was calculated
as = Ln(2/β), where β is the slope of the terminal elimination
phase obtained by least-squares linear regression. The maxi-
mum plasma concentration (Cmax)a n dt i m et oCmax (Tmax)
were determined directly from the observed data. The value
of CL/f was estimated using a nonlinear regression program
[12].
All experiments were conducted in accordance with
the Guidelines for Animal Experimentation, St. Marianna
University School of Medicine and had the approval of the
Animal Research Committee, Institute for Animal Exper-
imentation, St. Marianna University Graduate School of
Medicine.
2.2. OJ Study II. OJ and tap water was given to 8-week-
old male Sprague-Dawley rats on the same schedule and at
the same volume as in OJ study I. The small intestine and
liver were removed 1h after the last ingestion of OJ or tap
water, and plasma membrane fractions were prepared [13].
In brief, the small intestine and liver were homogenized in
100mM Tris-HCl, pH 7.5, containing a protease inhibitor
mixture (Roche Diagnostics, Mannheim, Germany). The
homogenate was centrifuged at 1500g for 15min, and the
supernatant was then centrifuged at 100,000g for 35min.
The resulting pellets were washed, resuspended in Tris HCl
buﬀer, and stored at −80◦C prior to analysis.
Mrp2 protein levels were analyzed using Western blot-
ting. Protein concentrations were determined using the Bio-
Rad Protein Assay (Bio-Rad, Hercules, CA, USA). Protein
samples (50μg each) were subjected to SDS-PAGE on 8%
SDS polyacrylamide gel. The proteins were transferred
to a nitrocellulose membrane (Hybond-ECL, Amersham
Bioscience, Piscataway, NJ, USA), and the membrane was
blocked with Tris-buﬀered saline (TBS)—0.1% Tween-20
containing 5% skim milk. The membrane was then incu-
bated for 1h with anti-MRP2 antibody (abcam, Cambridge,
UK) and anti-MRP2 antibody (Chemicon) diluted 1:100 in
TBS. After three washes with 0.1% Tween-20 in TBS (T-
TBS), the membrane was incubated for 1h with peroxide-
labeled antimouse IgG antibody (Cappel, Aurora, OH,
USA) diluted 1:2500 in T-TBS and developed with the
electrochemiluminescence(ECL)method(ECLplusWestern
blottingdetectionsystem,AmershamBioscience).Theinten-
sity of the staining of each membrane was measured with
ad e n s i t o m e t e r( D e n s i t o g r a p h ,A T T OC o . ,T o k y o ,J a p a n ) .
The intensity of bands was then measured.Journal of Biomedicine and Biotechnology 3
Levels of Mrp2 mRNA were determined with real-time
PCR (LightCycler, Roche Diagnostics) as described previ-
ously, with slight modiﬁcation [14]. Samples of liver and
intestinal tissue were then collected in the same manner as
for Western blot analysis. Total RNA was extracted from the
intestinal tissue with an RNA extraction kit (RNAgentsTotal
RNA Isolation System, Promega Co., Madison, WI, USA).
Two micrograms of total RNA were reversed transcribed
with 100U of Moloney murine leukemia virus reverse
transcriptase (RETROscript kit, Ambion Inc., Austin, TX,
USA) in 20μL of total reaction volume containing reverse-
transcriptase buﬀer, random primer, dNTP, and RNase
inhibitor. PCR was performed in 20μL of total reaction
volume containing 2μg of cDNA, primers speciﬁc for MRP2
and glyceraldehyde-3-aldehydro dehydrogenase (GAPDH),
MgCl2 3mmoL/L, and LightCycler FastStart DNA Master
SYBR Green I (Roche Diagnostics). The cycling protocol
consisted of one cycle of 10min at 95◦C followed by 40
cycles of denaturation for 15s at 95◦C, annealing for 10s
at 58◦C, and extension for 21s at 72◦C. The primers
for MRP2 were 5 -TTAACCGGGGACGTTG-3  (sense)
and 5 -GCCGATACCGCACTTGA-3  (antisense) and those
for GAPDH were 5 -CTGAGTATGTCGTGGAGTCTA-3 
(sense) and 5 -CTGCTTCACCACCTTCTTGAT-3  (anti-
sense). Serial dilutions of the standard cDNA were also used
for parallel ampliﬁcations. The threshold cycles (Ct)w e r e
calculated with LightCycler software (ver. 5.32). Standard
curveswere plottedwith Ct-versus-log cDNAquantities, and
the quantitiesof samples were determined from the standard
curves. In addition, Mrp2 mRNA levels were normalized to
those of GAPDH in each sample.
2.3. Hesperidin Study. Hesperidin instead of OJ was given
to 8-week-old male Sprague-Dawley rats using the same
schedule and volume as for the OJ studies. Tap water was
also given to the rats as a control. The hesperidin suspension
was prepared at a concentration of 79mg per 100mL of
tap water (0.079%). This concentration was equal to that
containedinOJ[15].ThepharmacokineticstudyofPRVand
measurement of Mrp2 protein and mRNA were performed
using the same methods as in OJ studies.
2.4. Statistical Analysis. Results are expressed as mean ±
SD. Mean values were compared with one-way analysis of
variance followed by the Scheﬀet es t.P valuesof less than .05
were considered statistically signiﬁcant.
3.Results
3.1. OJ Study I. Plasma PRV concentration-time proﬁles are
shown in Figure 1. After the administration of PRV, plasma
concentrations increased in a time-dependent manner and
subsequentlydecreased gradually.Signiﬁcant increases inthe
AUC (141%, P<. 05), Cmax (134%, P<. 05), and t1/2 (184%,
P<. 05) values of PRV were seen in the OJ group compared
with the control group, althoughCL/fvaluewas signiﬁcantly
decreased afterOJingestionand the tmax valuesdidnot diﬀer
signiﬁcantly (Table 1).
Table 1: Eﬀect of orange juice on the pharmacokinetic parameters
of single-orally administrated pravastatinon rats.
Parameter Control Orange Juice Ratio
(n = 6) (n = 6) (OJ/Cont)
Cmax (ng/mL) 120.8 ± 17.2 161.4 ± 26.4∗ 1.34
Tmax (min) 48.0 ± 12.5 50.0 ± 12.2 1.04
t1/2 (min) 75.5 ± 18.4 138.8 ± 58.5∗ 1.84
CL/f (L/hr) 105.0 ± 22.8 49.0 ± 17.4∗∗ 0.47
AUC (ng·hr/mL) 207.1 ± 21.4 291.3 ± 78.0∗ 1.41
The data are expressed as the mean ± S.D.
∗P<. 05 and ∗∗P<. 01, signiﬁcantlydiﬀerent from control.
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Figure 1: Eﬀect of orange juice (OJ) on the plasma concentration
of pravastatin (PRV) in Sprague-Dawley rats. OJ was administered
orally 8 times (1st day) and 5 times (2nd day) at hourly intervals.
The starting dose of OJ was 5mL/kg, and each consecutive dose was
2.5mL/kg.TapwaterinsteadofOJwasgivento thecontrolgroup. A
single dose of PRV at 100mg/kg p.o. was administered 1h after the
last ingestion of OJ or tap water. PRV levels were measured using
the HPLC method described in Section 2.
3.2. OJ Study II. The MRP2 protein level was signiﬁcantly
decreased in the OJ group to 36.7% in the liver(Figure 2(a)),
and to 33.9% in the intestine (Figure 2(b))c o m p a r e dw i t h
the respective control values. The Level of Mrp2 mRNA was
also signiﬁcantly decreased in the OJ group to 42.0% in the
liver(Figure 3(a)) and to66.4%in theintestine (Figure 3(b))
compared with the respective control values.
3.3. Hesperidin Study. Figure 4 shows the eﬀects of hes-
peridin on plasma PRV concentration-time proﬁles. Sig-
niﬁcant increases in the AUC (147%, P<. 05), the Cmax
(138%, P<. 05), and t1/2 (203%, P<. 05) values of4 Journal of Biomedicine and Biotechnology
0
20
40
60
80
100
12345678
Control OJ
P<. 001
I
n
t
e
n
s
i
t
y
o
f
M
R
P
2
p
r
o
t
e
i
n
(a) Liver
P<. 001
0
50
100
150
200
12345678
Control OJ
I
n
t
e
n
s
i
t
y
o
f
M
R
P
2
p
r
o
t
e
i
n
(b) Small intestine
Figure 2: Eﬀect of orange juice (OJ) on Mrp2 protein levels in both the liver (a) and small intestine (b) in rats. OJ or tap water was given
according to the same schedule as in Figure 1. The liver and small intestine were removed 1h after the last ingestion of OJ or tap water,
respectively, and plasma membrane fractions were prepared. Details of the Western blot analysis are described in Section 2.
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Figure 3: Eﬀect of orange juice (OJ) on the expression of Mrp2 mRNA in both the liver (a) and small intestine (b) in rats. Tap water or OJ
was given according to the same schedule as in Figure 1. The liver and small intestine were removed 1h after the last ingestion of OJ or tap
water, respectively, and total RNA was extracted from these tissues directly with the RNAgent Total RNA Isolation System. Levels of Mrp2
mRNA were determined with real-time PCR as described in Section 2.
PRV were observed in the heperidin group compared with
the control group, although CL/f value was signiﬁcantly
decreased after hesperidin ingestion and the tmax values did
not diﬀer signiﬁcantly (Table 2).
The Mrp2 protein level was signiﬁcantly decreased in
the hesperidin group to 50.1% in the liver (Figure 5(a))
and to 28.3% in the intestine (Figure 5(b))c o m p a r e dw i t h
the respective control values. The level of Mrp2 mRNA
was also signiﬁcantly decreased in the hesperidin group to
53.8% in the liver (Figure 6(a)) and to 70.4% in the intestine
(Figure 6(b)) of the respective control values.
4.Discussion
In the present study, we found signiﬁcantly increases in the
AUC and Cmax values and prolonged t1/2 of PRV in rats inJournal of Biomedicine and Biotechnology 5
Table 2:Eﬀect of hesperidin onthe pharmacokineticparameters of
single-orally administrated pravastatin on rats.
Parameter Control Hespridin Ratio
(n = 6) (n = 6) (Hes/Cont)
Cmax (ng/mL) 116.5 ± 10.5 160.1 ± 20.7∗ 1.38
Tmax (min) 52.5 ± 8.2 52.5 ± 12.6 1.00
t1/2 (min) 69.1 ± 3.7 140.3 ± 30.8∗ 2.03
CL/f (L/hr) 111.2 ± 44.4 55.9 ± 37.5∗ 0.55
AUC (ng·hr/mL) 213.5 ± 21.1 319.3 ± 23.7∗ 1.47
The data are expressed as the mean ± S.D.
∗P<. 05, signiﬁcantly diﬀerent from control.
∗P<. 05 and ∗∗P<. 01, versus control
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Figure 4:Eﬀect ofhesperidin (Hes)ontheplasmaconcentrationof
pravastatin(PRV) inSprague-Dawley rats.Ahesperidin suspension
was prepared at a concentration of 79mg per 100mL of tap water
(0.079%). The suspension instead of OJ was given according to the
same schedule and volume as in the OJ study (Figure 1).
the OJ group. These results suggest that OJ intake increases
t h er a t eo fa b s o r p t i o no fP R Vb a s e do nt h ei n c r e a s e dCmax
and decreases the rate of elimination of PRV from the
systemic circulation based on the prolonged t1/2.
PRV is moved by transporters [16–19], while CYP3A4
playsonlyaminorroleinthebiotransformation ofPRV[20].
Therefore,oxidativeenzymesintheintestineorlivermay not
be involved in changes in the pharmacokinetics (Cmax,A U C ,
and t1/2) of PRV with OJ intake.
Mrp2 participates in the biliary excretion of PRV in the
liver [18, 19], and the transporter is also present in the small
intestine [21–23]. Mrp2 may play the role of an excretion
transporterinthesmallintestine.However,therehasbeenno
report ontheinﬂuenceofOJonMrp2 proteinand itsmRNA
levels in the liver and small intestine. Here we found that
the amount of Mrp2 protein decreased in both the liver and
small intestine after the ingestion of OJ. Since Mrp2 mRNA
levels also decreased with the ingestion of OJ, it was thought
that the loss of Mrp2 protein was a result of decreased gene
expression.
Mrp2, an organic anion transporter, excretes xenobiotics
from the apical membranes of intestinal epithelial cells into
the intestinal lumen [24]. Therefore, the increase in Cmax
after ingestion of OJ is thought to be due to the relative
increase in PRV absorption in the small intestine, which
is based on the decrease in Mrp2 expression in the small
intestine caused by OJ.
Eighty percent of PRV is excreted via the liver [25], and
Mrp2 participates in this excretion [18, 19]. Therefore, it
was also thought that the decrease in hepatic Mrp2 after the
ingestion of OJ caused the decrease in the biliary excretion
of PRV (includinga decrease in ﬁrst-pass excretion), and this
decrease may cause the prolongation of t1/2 and the increase
in the Cmax of PRV.
We next investigated whether a speciﬁc component in
OJ reduces Mrp2 levels in the liver and small intestine. The
pharmacokinetic parameters (Cmax,A U C ,a n dt1/2)o fP R V
changed after the ingestion of OJ (in this study) but not
after the ingestion of GFJ [7]. These results suggest that a
c o m p o n e n tt h a ti sm o r ea b u n d a n ti nO Jt h a ni nG F Jr e a c t s
with the transporter for PRV.
The predominant ﬂavanone in blood is hesperetin when
OJ is ingested and naringenin when GFJ is ingested [8, 9].
These ﬂavanones are common in plants where they are
conjugated to glycosides. Hesperetin is present in oranges as
hesperetin-7-O-rutinoside (hesperidin). For these reasons,
we also investigated the inﬂuence of hesperidin, instead of
hesperetin, on the pharmacokinetic parameters (Cmax,A U C ,
and t1/2) of PRV and the expression of Mrp2 protein and
mRNA in the rat small intestine and liver.
Hesperidin signiﬁcantly increased the AUC, Cmax,a n d
t1/2 values of PRV. The level of Mrp2 protein and mRNA
decreased with the ingestion of hesperidin in the small
intestine and liver.
WhenwecomparedtheeﬀectsofOJandhesperidin,both
increasedthebioavailabilityofPRVinrats.Sincethequantity
of hesperidin ingested was the same as the quantity in OJ, it
was suggested that the decrease in Mrp2 expression in the
liver and small intestine after the ingestion of OJ was caused
by the hesperidin in the juice.
In rats, it was reported that oatp2 and oatp3 are also
localized at the apical membrane of intestinal epithelial cells
[26]. PRV is a substrate for oatp1 and oatp2 in several tissues
[27].The physiologicroleoftheintestinal OATP family isthe
transport of drugs from the intestinal tract into the portal
circulation. In the liver, PRV is taken up via a mechanism
mediated by the OATP family (oatp1, oatp2 [OATP C]) from
the portal circulationto hepatocytes[28].F orth i sr ea s on ,w e
investigated the eﬀects of OJ or hesperidin (2-day ingestion)
ontheleveloftheoatp2proteinintheliverorsmall intestine.
Consequently, although the data are not shown, the oatp2
protein level increased in the small intestine after 2-day OJ
ingestion, but the oatp2 protein level in liver did not change.6 Journal of Biomedicine and Biotechnology
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Figure 5: Eﬀect of hesperidin on Mrp2 protein levels in both the liver (a) and small intestine (b) in rats. Hesperidin instead of OJ was given
to 8-week-old maleSprague-Dawley ratsaccording to thesameschedule andvolumeasinthe OJstudy. Tap waterwasalsogivenas acontrol.
The hesperidin solution was prepared at a concentration of 79mg per 100mL of tap water. The small intestine and liver were removed 1h
after the last ingestion of hesperidin. Western blot analysiswas performed using the same methods as in the in vitro OJ study.
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Figure 6:Eﬀects of hesperidin on the expression of Mrp2 mRNA in both the liver (a) and smallintestine (b) in rats. Determination of Mrp2
mRNA was performed using the same methods as in the in vitro OJ study.
A similar result was obtained after the 2-day ingestion of
hesperidin. Our ﬁnding that the oatp2 level increased with
OJ or hesperidin intake may be also one mechanism of the
increase in the PRV AUC value.
It will be necessary to examine the eﬀects of the OJ
ingestion on another transporter that participates in the
transport of PRV. Further studies may also needed since oat3
in particular is believed to contribute to the active renal
transport of PRV.
As the amount of hesperidin administered was pre-
adjusted to the amount present in OJ, near quantitative
evaluation may be possible. When we compared the results
in the OJ and hesperidin groups, the inhibitory results
were similar. Based on this similarity, we assumed that the
inhibitory mechanism may be simple because most of the
eﬀect of OJ could be attributed to hesperidin.
We did not perform a conﬁrmation study using OJ with
its hesperidin content extracted. Therefore, it is possible that
other factors may have contributed to the results obtained.
In addition, the possibility that other pharmacokinetic
factors like metabolism or excretion may have played a role
in increasing the Cmax and AUC values cannot be ruledJournal of Biomedicine and Biotechnology 7
o u t ,b e c a u s ew ed i dn o tm e a s u r ep r e c i s eb i o a v a i l a b i l i t y .
The concentration curve appears to have a slow decreasing
sequence. We therefore may need to explore more detailed
pharmacokinetic parameters in future studies.
In conclusion, hesperidin contained in OJ may be the
substance inhibiting Mrp2.
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